The world first vaccine for COVID-19 obtained clinical approval in Hong Kong
- COVID-19 infection increases risk of a range of neurological diseases,
- Cancer patients eating ice cream can reduce this side effect of chemotherapy
- Gut microbes may become a new therapy for depression and anxiety
- The risk of Alzheimer’s disease increases by 50-80% within a year after COVID-19 infection
- Hong Kong will launch monkeypox vaccination for high-risk groups in October
- Ebola (Sudan strain) outbreak in Uganda
The world first vaccine for COVID-19 obtained clinical approval in Hong Kong
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
The world first vaccine for COVID-19 obtained clinical approval in Hong Kong.
The world’s first! Two Omicron inactivated vaccines from China Bio-Beijing and Wuhan Institute of Biological Products have obtained clinical approval from Hong Kong
Recently, two novel coronavirus inactivated vaccines (Omicron variant, hereinafter referred to as “O strain ” ) developed by SINOPHARM China Bio-Beijing Institute of Biological Products and Wuhan Institute of Biological Products have been approved by the University of Hong Kong and the medical administration.
With the review and approval of the Research Ethics Committee of the Hong Kong Island Western Hospital Cluster, and the clinical trial approval from the Hong Kong Pharmacy and Poisons Board, it was officially approved to conduct sequential immunization clinical research on the COVID-19 vaccine in Hong Kong.
Since the outbreak of the Omicron variant, Sino Biological immediately organized a scientific research team to start the research and development of a vaccine against the Omicron strain.
The affiliated Beijing Institute of Biological Products and Wuhan Institute of Biological Products have gone all out to carry out scientific research and developed BIBP-new coronavirus inactivated vaccine (O strain) and WIBP-new coronavirus inactivated vaccine (O strain) at the first time.
Both vaccines were inoculated into Vero cells with Omicron strain, and were made by culture, inactivation, purification, and adsorption with aluminum hydroxide adjuvant .
After the successful development of the vaccine, China Biotechnology actively carried out in-depth cooperation with the University of Hong Kong, and submitted an ethical application and a clinical trial application to the Hong Kong Research Center as soon as possible, and successfully obtained the ethical approval and clinical approval on April 12 and April 13 respectively. .
In the next step, Sino Bio will use a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the COVID-19 vaccine to evaluate the BIBP-novel coronavirus inactivated vaccine The safety and immunogenicity of two vaccines (O strain) and WIBP-novel coronavirus inactivated vaccine (O strain).
Sino Bio will actively and efficiently promote the clinical trial work of the COVID-19 vaccine of the Ormicon strain, and make every effort to complete the clinical trial as soon as possible and put it into official use .
The world first vaccine for COVID-19 obtained clinical approval in Hong Kong
(source:internet, reference only)
Disclaimer of medicaltrend.org
